.Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01B_Antimalarials.P01BC02_Mefloquine.Mefloquine .Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01B_Antimalarials.P01BC02_Mefloquine.Mefloquine| name: | Mefloquine |
| ATC code: | P01BC02 | route: | oral |
| n-compartments | 2 |
Mefloquine is an antimalarial medication used for the treatment and prevention of malaria, particularly caused by Plasmodium falciparum. It is typically used as a prophylactic agent for travelers to endemic regions and as a treatment for uncomplicated malaria. Mefloquine is approved and used in clinical practice but its use is limited by potential neuropsychiatric side effects.
Pharmacokinetic parameters in healthy adult volunteers after oral administration.
Simpson, JA, et al., & White, NJ (1999). Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clinical pharmacology and therapeutics 66(5) 472–484. DOI:10.1016/S0009-9236(99)70010-X PUBMED:https://pubmed.ncbi.nlm.nih.gov/10579474
Reuter, SE, et al., & Olliaro, PL (2015). Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. The Journal of antimicrobial chemotherapy 70(3) 868–876. DOI:10.1093/jac/dku430 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25377567
Charles, BG, et al., & Edstein, MD (2007). Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment. European journal of clinical pharmacology 63(3) 271–278. DOI:10.1007/s00228-006-0247-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17216435